Literature DB >> 25632482

The anti-rheumatoid arthritis property of the folk medicine Dianbaizhu (Gaultheria leucocarpa var. yunnanensis, Ericaceae).

Meng Xie, Yi Lu, Cheng Yan, Rui Jiang, Weirui Liu, Zizhen Liu, Guanling Xu, Yue Yang, Xia Zhang, Yuxin Tian, Yan Wang, Jianqiu Lu, Gaimei She.   

Abstract

The Chinese folk medicine Dianbaizhu, consisting of Gaultheria species, is widely used for the treatment of rheumatoid arthritis by several minority nationalities. The species and plant parts of this genus used as Dianbaizhu in clinical application are confused. In order to elucidate the species and the medicinal parts, as well as to ascertain the effective components and the probable optimal source of Dianbaizhu, the different plant parts and polarity fractions of its mainstream species, G. leucocarpa var. yunnanensis were investigated. The inhibition of nitric oxide and tumor necrosis factor produced in macrophage J774 were used to assess the anti-inflammatory effect of those samples. G. leucocarpa var. yunnanensis may be the preferred species for anti-RA effect. The underground parts of this taxon showed the best anti-inflammatory and anti-RA activities; the n-butanol and water fractions of the underground parts may be the most anti-RA active.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25632482

Source DB:  PubMed          Journal:  Nat Prod Commun        ISSN: 1555-9475            Impact factor:   0.986


  2 in total

1.  Effect of Jiawei Fengshining on Synovial Cell Apoptosis and TGF-β1/Smad Signaling Pathway in Rats with Rheumatoid Arthritis.

Authors:  Xiaojun Dong; Yuan Gan; Lina Ding; Fujia Zeng; Dou Ding
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-21       Impact factor: 2.629

2.  The protective effect of gentisic acid on rheumatoid arthritis via the RAF/ERK signaling pathway.

Authors:  Xiaojun Dong; Qi Zhang; Fujia Zeng; Mingxing Cai; Dou Ding
Journal:  J Orthop Surg Res       Date:  2022-02-20       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.